The chaos of hypertension guidelines for chronic kidney disease patients

• Published in: Clinical kidney journal Vol. 12; no. 6; pp. 771 - 777
• Main Authors: Castillo-Rodriguez, Esmeralda, Fernandez-Fernandez, Beatriz, Alegre-Bellassai, Raquel, Kanbay, Mehmet, Ortiz, Alberto
• Format: Journal Article
• Language: English
• Published: Oxford University Press 01-12-2019
• Subjects: Analysis; Angiotensins; Antihypertensive agents; Chronic kidney failure; Diseases; Drug therapy; Hypertension; Kidney diseases; Medical practice; Nihilism; Physicians; Practice guidelines (Medicine); Renin-angiotensin system; Spain; blood pressure targets; treatment; chronic kidney disease; blood pressure thresholds; hypertension; renin–angiotensin system
• ISSN: 2048-8505; 2048-8513
• DOI: 10.1093/ckj/sfz126

Three major guidelines deal with blood pressure thresholds and targets for antihypertensive drug therapy in chronic kidney disease (CKD) patients: the 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease; the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; and the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. However, a careful reading of the three guidelines leaves the practicing physician confused about the definition of CKD, how hypertension and secondary hypertension should be diagnosed in CKD patients and what the blood pressure thresholds, targets and compelling indications of antihypertensive drug therapy should be for this population. Current guidelines refer to different CKD populations and propose different definitions of hypertension, different thresholds to initiate antihypertensive therapy in CKD patients and different BP targets compelling antihypertensive drug use. The different bodies producing guidelines should work together towards a unified definition of CKD, a unified concept of hypertension and unified BP thresholds and targets for hypertensive drug therapy for CKD patients. Otherwise they risk promoting confusion and therapeutic nihilism among physicians and patients.